Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration
Faricimab demonstrated sustained anatomical improvement and treatment durability over 2.5 years, with a subset of patients showing lasting benefit.
Authors
- Danny A. Mammo (ORCID: https://orcid.org/0000-0002-7496-5118)
- Amy Babiuch (ORCID: https://orcid.org/0000-0002-0782-2694)
- Nitesh Mohan (ORCID: https://orcid.org/0000-0001-6929-9504)
- Sapna Sharma (ORCID: https://orcid.org/0000-0001-5692-5668)
- Germán Barbosa
- Katherine E. Talcott
- Peter K. Kaiser
- Andrei Szigiato
- Justis P. Ehlers
- Victor Bellanda
- Aleksandra Rachitskaya
- Matthew J. Schulgit
- Sunil K. Srivastava
- Alex Yuan
Institutions
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Cleveland Eye Clinic (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Ophthalmic surgery, lasers & imaging retina
- Published
- 2026-03-16
- DOI
- https://doi.org/10.3928/23258160-20260127-02
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00